Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
CRO giant Parexel has updated its technology for patient randomization and clinical supply management, touting the latest version as a valuable tool for speeding up the process of designing studies.
DaVita Clinical Research, which handles outsourced trials for the kidney care giant, is expanding its European presence, bringing in global experts to extend its network of R&D sites.
BioClinica has inked a deal with consulting firm Kinapse to help spread the adoption of its risk-based monitoring service, a targeted approach to keeping tabs on trials.
The European Medicines Agency has affirmed its January recommendation, calling for the suspension of more than 700 products tied to improprieties at a GVK Biosciences facility in India.
U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.
Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.
A group of Quintiles shareholders including the CRO's founder made about $770 million in a secondary stock offering, selling a bulk of shares back to the company and cashing in on its success.
A year removed from taking a private equity buyout, U.K. CRO Quotient Clinical has watched demand for its services spike, the company said, plotting some major investments to keep the pace of growth.
CRO inVentiv Health is amping up its capacity in regulatory compliance to prepare for changes in European trial rules, unveiling a global database it claims can help sponsors avoid costly confusion.
WuXi PharmaTech, China's largest CRO, again boosted its revenue by double digits last quarter, keeping the pace of growth as it considers an offer to go private.